Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$2.13 +3.9%	$1.40	$0.69 ▼ $3.94	$413.33M	0.82	6.79 million shs	4.30 million shs
HLVX HilleVax	$2.07	$2.04	$1.34 ▼ $2.17	$103.79M	0.77	955,799 shs	344,238 shs
REPL Replimune Group	$5.60 +6.7%	$7.87	$2.68 ▼ $17.00	$409.79M	0.67	17.99 million shs	2.70 million shs
RGNX REGENXBIO	$8.11 +0.5%	$8.53	$5.03 ▼ $13.48	$407.65M	1.11	689,079 shs	387,766 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	+0.49%	+5.67%	+78.26%	+155.29%	+15.17%
HLVX HilleVax	+0.49%	0.00%	+0.98%	+11.29%	+13.11%
REPL Replimune Group	-0.57%	+3.04%	-57.39%	-40.07%	-50.38%
RGNX REGENXBIO	+0.50%	-9.63%	-4.95%	-18.15%	-32.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	3.8078 of 5 stars	3.4	1.0	3.9	2.5	1.7	0.6
HLVX HilleVax	1.6117 of 5 stars	1.0	4.0	0.0	1.8	3.3	1.3
REPL Replimune Group	4.4707 of 5 stars	4.2	2.0	4.5	2.3	2.5	0.6
RGNX REGENXBIO	4.3553 of 5 stars	3.4	3.0	4.6	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	228.64% Upside
HLVX HilleVax	2.00	Hold	$2.00	-3.38% Downside
REPL Replimune Group	2.33	Hold	$7.67	36.90% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	249.88% Upside

Current Analyst Ratings Breakdown

Latest HLVX, ESPR, REPL, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
8/8/2025	HLVX HilleVax	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	RGNX REGENXBIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $17.00
8/8/2025	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $37.00
8/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	1.29	$0.03 per share	84.91	($2.15) per share	-0.99
HLVX HilleVax	N/A	N/A	N/A	N/A	$2.95 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A
RGNX REGENXBIO	$83.33M	4.92	N/A	N/A	$4.23 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.41%	11/6/2025 (Estimated)
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	11/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	N/A
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	11/5/2025 (Estimated)

Latest HLVX, ESPR, REPL, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million
8/6/2025	Q2 2025	HLVX HilleVax	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.15	0.76
HLVX HilleVax	N/A	26.39	26.39
REPL Replimune Group	0.21	6.94	6.94
RGNX REGENXBIO	N/A	3.13	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
HLVX HilleVax	86.42%
REPL Replimune Group	92.53%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
HLVX HilleVax	24.90%
REPL Replimune Group	5.20%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	201.62 million	198.20 million	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable

HLVX, ESPR, REPL, and RGNX Headlines

Recent News About These Companies

HC Wainwright Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)

August 21 at 8:10 AM | marketbeat.com

Voss Capital LP Has $2.79 Million Position in REGENXBIO Inc. $RGNX

August 21 at 6:52 AM | marketbeat.com

Delay hits Regenxbio BLA review

August 20 at 5:35 PM | thepharmaletter.comT

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 20 at 2:54 AM | marketbeat.com

REGENXBIO Inc.: REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

August 19 at 12:44 AM | finanznachrichten.de

Regenxbio announces FDA review extension for RGX-121 BLA

August 19 at 7:44 PM | msn.com

Regenxbio FDA delay ‘not a needle mover,’ says Leerink

August 19 at 7:44 PM | msn.com

Analyst Expectations For Regenxbio's Future

August 19 at 7:44 PM | benzinga.com

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

August 18 at 5:00 PM | prnewswire.com

XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX)

August 13, 2025 | marketbeat.com

Are Options Traders Betting on a Big Move in Regenxbio Stock?

August 12, 2025 | msn.com

REGENXBIO (NASDAQ:RGNX) Stock Rating Lowered by Wall Street Zen

August 11, 2025 | americanbankingnews.com

REGENXBIO's (RGNX) "Buy" Rating Reiterated at Chardan Capital

August 11, 2025 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Pass Below 50-Day Moving Average Following Weak Earnings

August 10, 2025 | marketbeat.com

Royal Bank Of Canada Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $17.00

August 10, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts

August 9, 2025 | uk.finance.yahoo.com

Barclays Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $37.00

August 9, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital

August 9, 2025 | marketbeat.com

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

August 7, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HLVX, ESPR, REPL, and RGNX Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$2.13 +0.08 (+3.90%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 -0.02 (-1.17%)

As of 07:56 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

HilleVax NASDAQ:HLVX

$2.06 0.00 (-0.24%)

As of 04:00 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Replimune Group NASDAQ:REPL

$5.60 +0.35 (+6.67%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 -0.10 (-1.79%)

As of 07:38 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REGENXBIO NASDAQ:RGNX

$8.11 +0.04 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$8.22 +0.11 (+1.36%)

As of 07:48 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time